Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Kymera Therapeutics is viewed favorably because KT-621 has shown enough early clinical momentum to support accelerated development, with Phase 2b atopic dermatitis topline data now expected by year-end 2026 and a Phase 3 start targeted for mid-2027. The thesis is strengthened by management’s apparent “pharma-like” ambition, potential for >10 Phase 3s by 2028-29, and evidence that an oral, biologic-like therapy could address the large population of patients still sitting on the sidelines in immunology. Financially, the model implies 2026E/2027E/2028E revenues of $73M/($13M)/($25M), cash runway into 2029, and meaningful upside if KT-621 can expand into dermatology and respiratory indications.

Kymera Therapeutics is a clinical-stage biotech with no approved products, so its valuation depends heavily on uncertain readouts from KT-621 and IRAK4 rather than recurring cash flow. The investment case is weakened by clear execution risks, including disappointing efficacy or safety, delays in R&D and regulation, difficult enrollment, and the possibility that early data do not translate into later-stage success. Even with encouraging market potential in underpenetrated Th2 diseases, it still faces strong competition, pricing pressure in orphan areas, and the risk of needing additional capital if development costs rise.